Tagged with Vaccines

Russia Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable tool in the global fight against COVID-19. Sputnik V is now approved in a number of countries, but questions are…

Asia-Pacific UPS APAC’s Bee Lim describes how the logistics giant responded to the unprecedented challenges thrown up by the COVID-19 pandemic, the trends that the pandemic has accelerated in the region, and the talent profiles that UPS is looking for to ensure future success.   The capabilities that we have built…

Global The issue of COVID-19 vaccine access in developing nations has thrust intellectual property (IP) into global headlines. Against the backdrop of heated arguments both for and against an IP waiver for COVID-related products, the global pharma industry has launched a new initiative on IP, asserting its crucial importance to continued…

USA The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the day after that, another two percent. However, the Massachusetts-based company’s CEO Stephane Bancel remains unconcerned and believes that their successful vaccine is just the beginning of the mRNA era…

Switzerland Swiss-headquartered ADIENNE has made recent headlines after being announced as the first European company to manufacture Russia’s Sputnik V COVID-19 vaccine. President and Founder Antonio Francesco Di Naro explains how the company’s deal with the Russian Direct Investment Fund happened and some of the challenges related to the manufacturing process.…

Switzerland In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production lines for the manufacture of antibody-drug conjugates, and a ramping up of its workforce dedicated to the production of ingredients…

USA In a shock move, Joe Biden’s administration looks set to support a waiver on intellectual property (IP) protections for COVID-19 vaccines.   The decision – which comes amid worrying situations in India and other counties and increasing concern that vaccine-resistant strains of COVID could undermine a global recovery – has…

Turkey As the international community continues its quest to vaccinate the global population against COVID-19, shortages of already approved vaccines have put many countries on the waiting list. Approved vaccines from the United States, Europe, China and Russia have taken the lead but new candidates from the rest of the world…

Global On World Intellectual Property (IP) Day 2021, the innovative biopharmaceutical industry came together to launch a new initiative foregrounding the benefits to patients and to society at large of a robust IP framework. Under the INTERPAT umbrella, 25 industry members and associations launched the ‘IP Principles for Advancing Cures and…

UK Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of COVID-19 and Brexit seem set to muddy the waters of cross-border pharma trade for some time to come.   Five…

Korea The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and Samsung Bioepis’ first steps into the Australian market.   ‘Now is best time to develop Korean blockbuster drug’ (Korea Biomedical…

Mexico While Mexico struggles with its COVID-19 vaccination campaign, residents of the country’s northern states have begun flying to the United States in search of a shot. Fearful of “fake vaccines” in their home country, some Mexicans are risking their tourism visas, and in some cases their lives, to be inoculated…